Question follow-through · 19756

Business Growth Service

To ask the Secretary of State for Business, Innovation, Science and Trade, pursuant to the answer of 14 July 2026 to question 16800, what specific funding has been allocated within the Business Growth Service budget for fiscal year 2026-27 explicitly to h

answeredDepartment for Business, Innovation, Science and Trade

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body
Department for Business, Innovation, Science and Trade
Tabled
16 Jul 2026
Target answer date
2 Sept 2026
Answer
2 Sept 2026 · 48 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

Votes on this topic

These Commons divisions share a topic label. The question did not necessarily lead to a vote.

Recorded timeline

  1. 16 Jul 2026

    Question tabled

    To ask the Secretary of State for Business, Innovation, Science and Trade, pursuant to the answer of 14 July 2026 to question 16800, what specific funding has been allocated within the Business Growth Service budget for fiscal year 2026-27 explicitly to h

  2. 2 Sept 2026

    Target answer date

    Date supplied by the official written-questions record.

  3. 2 Sept 2026

    Answer published

    Although no specific funding has been allocated to the Business Growth Service (BGS) for financial year 2026-27 to help UK SMEs develop business continuity plans, DBT supports small and medium sized businesses become more resilient in the event of major d...

Open official record

Official data retrieved 28 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

No later same-department questions indexed.

This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.